US FDA accepts and grants priority review status to AstraZeneca’s …
网页4 天之前 · AstraZeneca’s supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The Food and Drug Administration (FDA) grants Priority Review to ...
Theriva Biologics announces positive outcome of DSMC review in …
网页3 天之前 · Theriva Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced a positive outcome from the Data and Safety Monitoring Committee (DSMC) review of results from the second Cohort of its phase 1b ...
Halozyme expands global collaboration and license agreement …
网页3 天之前 · Saturday, October 5, 2024, 11:00 Hrs [IST] Halozyme Therapeutics, Inc., a biopharmaceutical company, announced that argenx has nominated four new targets under its global collaboration and license agreement that provides argenx exclusive access to Halozyme's ENHANZE drug delivery technology, a proprietary recombinant human hyaluronidase PH20 ...
Liquidia, Pharmosa Biopharm expand collaboration to develop …
网页4 天之前 · The L606 suspension uses Pharmosa’s proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period and reducing local irritation of the upper respiratory tract. L606 is currently being evaluated in an open-label study in the United ...
US FDA grants Emergency Use Authorization to Novavax 2024 …
网页2024年9月2日 · US FDA grants Emergency Use Authorization to Novavax 2024-2025 Formula Covid-19 vaccine to prevent Covid-19 in individuals aged 12 and older
News - Pharmabiz.com
网页2024年9月30日 · Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, pharma projects, pharma export & import, pharma laws & documents, pharma policies, pharma events, pharma company profiles, pharma studies, pharma marketing.
US FDA grants Priority Review status Novartis’ Scemblix for …
网页2024年7月31日 · US FDA grants Priority Review status Novartis’ Scemblix for treatment of adults with newly diagnosed CML: East Hanover Wednesday, July 31, 2024, 12:00 Hrs [IST]
Takeda’s vedolizumab receives US FDA approval to treat …
网页2024年4月20日 · Osaka, Japan. Saturday, April 20, 2024, 16:00 Hrs [IST] Takeda announced that the US FDA has approved Entyvio (vedolizumab) subcutaneous administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) Entyvio. The subcutaneous administration of Entyvio was ...
Boehringer Ingelheim’s Cyltezo to treat multiple chronic …
网页Friday, May 3, 2024, 11:00 Hrs [IST] Boehringer Ingelheim Group, one of the largest producers of biologic medicines in the world, announced that the US Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company's interchangeable biosimilar to Humira (adalimumab), to ...
AstraZeneca to acquire clinical-stage biopharma company, Fusion …
网页2024年3月20日 · AstraZeneca to acquire clinical-stage biopharma company, Fusion Pharma for $2 billion: Cambridge, UK Wednesday, March 20, 2024, 11:00 Hrs [IST] AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).